American Association for Cancer Research
21598290cd150370-sup-147434_2_supp_0_nsz4cr.pdf (775.98 kB)

Supplementary Figure S5 from Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma

Download (775.98 kB)
journal contribution
posted on 2023-04-03, 20:43 authored by Russell J.H. Ryan, Yotam Drier, Holly Whitton, M. Joel Cotton, Jasleen Kaur, Robbyn Issner, Shawn Gillespie, Charles B. Epstein, Valentina Nardi, Aliyah R. Sohani, Ephraim P. Hochberg, Bradley E. Bernstein

Supplementary Figure S5. Additional details regarding candidate MYC enhancers identified in B cell lymphomas.



B-cell lymphomas frequently contain genomic rearrangements that lead to oncogene activation by heterologous distal regulatory elements. We used a novel approach called “pinpointing enhancer-associated rearrangements by chromatin immunoprecipitation,” or PEAR-ChIP, to simultaneously map enhancer activity and proximal rearrangements in lymphoma cell lines and patient biopsies. This method detects rearrangements involving known cancer genes, including CCND1, BCL2, MYC, PDCD1LG2, NOTCH1, CIITA, and SGK1, as well as novel enhancer duplication events of likely oncogenic significance. We identify lymphoma subtype–specific enhancers in the MYC locus that are silenced in lymphomas with MYC-activating rearrangements and are associated with germline polymorphisms that alter lymphoma risk. We show that BCL6-locus enhancers are acetylated by the BCL6-activating transcription factor MEF2B, and can undergo genomic duplication, or target the MYC promoter for activation in the context of a “pseudo-double-hit” t(3;8)(q27;q24) rearrangement linking the BCL6 and MYC loci. Our work provides novel insights regarding enhancer-driven oncogene activation in lymphoma.Significance: We demonstrate a novel approach for simultaneous detection of genomic rearrangements and enhancer activity in tumor biopsies. We identify novel mechanisms of enhancer-driven regulation of the oncogenes MYC and BCL6, and show that the BCL6 locus can serve as an enhancer donor in an “enhancer hijacking” translocation. Cancer Discov; 5(10); 1058–71. ©2015 AACR.See related commentary by Mack et al., p. 1018.This article is highlighted in the In This Issue feature, p. 1005